Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-21-015298 Act: 34 Size: 7 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-21-015265 Act: 34 Size: 445 KB 网页链接
$Nabriva Therapeutics(NBRV)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-21-004111 Act: 33 Size: 1 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-132491 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-132492 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-132463 Size: 5 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001104659-21-132349 Act: 33 Size: 644 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-124665 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-124668 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ S-1 General form for registration of securities under the Securities Act of 1933 Accession Number: 0001104659-21-124612 Act: 33 Size: 1 MB 网页链接